Trial Profile
A retrospective study evaluating efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology